Clinical Trials Arena on MSN17h
Immunovant will not seek approval for MG therapy, despite hitting endpointsImmunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback